George LIU

Dr. George Liu is the Head of Early Development and Scientific Operation at Harbour BioMed (HBM). Before joining HBM, he was Director of Clinical Pharmacology for Novartis Oncology where he is responsible for clinical pharmacology perspectives of oncology full development and managing early clinical development and life cycle management (LCM) in China. Prior to joining Novartis, Dr. Liu worked at Sanofi, GSK, and Guilford Pharmaceuticals where he held positions with increasing responsibilities for both nonclinical and clinical pharmacokinetics and contributed to the discovery and/or development, including regulatory approval, of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.